Developer docs
API playgroundTry for free, no card

Search company profiles

ZEPHYRx

Full company profile

uuid0009ezs

Namestring
ZEPHYRx
Legal namestring
ZEPHYRx LLC
Websiteurl
zephyrx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

ZEPHYRx is a digital health SaaS company providing cloud-based remote respiratory monitoring (RRM) for two primary customer segments: healthcare providers managing patients with chronic respiratory conditions (COPD, cystic fibrosis, pulmonary fibrosis, asthma, and related indications), and clinical research organizations, sponsors, and academic investigators running decentralized and hybrid respiratory clinical trials. Founded in 2019 and headquartered in Troy, New York, the company operates as ZEPHYRx LLC (Delaware-domiciled), is a subsidiary of My Music Machines Inc., and is majority-owned by Chairperson Sue Whalen with no institutional venture or growth-equity capital disclosed. The company originated from an NIH/NHLBI-funded STTR grant awarded to cofounder Michael DiCesare to develop a respiratory therapy device using interactive gaming and music, and gained initial traction during the COVID-19 pandemic by distributing connected spirometers for at-home pulmonary function testing to top US hospitals.

The ZEPHYRx platform is a three-layer architecture: a patient-facing Breathe Easy mobile app (iOS, Android, and Amazon), FDA-cleared Bluetooth-enabled MIR Spirobank spirometers (single-patient home and multi-patient point-of-care kiosk variants), and a cloud-based Provider Dashboard that delivers real-time video coaching, AI-driven spirometry overreading against ATS/ERS 2019 standards, custom surveys, compliance monitoring, and automated alerts. The platform captures spirometry endpoints (FVC, FEV1, SVC, Peak Flow), FeNO via NIOX integration, and ePRO/eCOA, and is HIPAA, GDPR, CCPA, and SOC 2 compliant. Trial-side modules include Kiosk for point-of-care testing, Home for at-home monitoring, and a Gateway API integration layer; healthcare-side modules include EMR integration and SSO connectors. Strategic integrations extend the platform to Morgan Scientific (ComPAS2), RxCap, ActiGraph wearables, and the Target ALS Data Engine.

ZEPHYRx monetizes through a per-patient-per-month subscription for healthcare providers (which only bills when a test is performed), hardware resale of MIR spirometers (ZEPHYRx is MIR's largest reseller), and clinical research services including trial setup, project management, global logistics, and data management. Distribution is hybrid: direct enterprise field sales, an exclusive North American channel partnership with MIR, CRO and RPM partner programs for white-label and indirect distribution, and self-serve patient app distribution through app stores. To date the company has delivered more than 40,000 spirometers, supported 50+ clinical studies covering CF, ALS, COPD, asthma, IPF, ILD, and other respiratory indications, and monitored 10,000+ research participants remotely.

Short descriptiontext

ZEPHYRx is a digital health SaaS platform combining FDA-cleared Bluetooth spirometers, a patient mobile app, and a cloud provider dashboard with AI spirometry overreading. It serves healthcare providers managing chronic respiratory patients and clinical research organizations running decentralized respiratory trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTroy, United States
HQ citystring
Troy
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote respiratory monitoring, decentralized clinical trials, spirometry cloud platform, pulmonary function testing, digital health SaaS
Industry3 codes
PRIMARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAI
Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Remote Respiratory Monitoring (Digital Health SaaS)
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Subscription - Remote Respiratory Monitoring
TypeSubscription Recurring
Description

Subscription-based model for cloud platform access and remote respiratory monitoring services. Subscribers pay a flat rate per patient per month with testing-inclusive pricing - if no test is performed, no charge; multiple tests still incur only the flat rate. Includes reimbursement support services, patient onboarding, and technical support.

zephyrx.com
2Spirometer Hardware Sales
TypeHardware Sales
Description

Sales of MIR Spirobank Smart and Spirobank II Smart BLE FDA-cleared spirometers. ZEPHYRx is the largest reseller of MIR spirometers. Spirometers are sold to healthcare practices and clinical research organizations for at-home and point-of-care use.

zephyrx.com
3Clinical Research Services
TypeProfessional Services
Description

Comprehensive services for decentralized and hybrid clinical trials including trial setup and kickoff, project management, data management, global logistics, 24/7 support, and compliance with GCP standards.

zephyrx.com
4RPM Reimbursement Support
TypeManaged Services
Description

Reimbursement services included in subscription to help providers navigate home spirometry reimbursement challenges with ongoing support and documentation for CPT code submissions.

zephyrx.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Subscription - Cost-Effective RRM Solution
ModelSubscriptionBilling cadenceMonthly
Notes

Subscribers pay a flat rate per patient per month and only if a test is performed. If a test isn't performed - you pay $0. If they perform 10 tests - you still only pay the flat rate. Includes reimbursement services and patient onboarding support.

zephyrx.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Breathe Easy
Description

Free patient-facing mobile application for performing pulmonary function tests, featuring real-time video coaching, PFT notifications, and gamified breathing exercises.

zephyrx.com
Core offering1 text field

ZEPHYRx provides a cloud-based Remote Respiratory Monitoring (RRM) platform that combines FDA-cleared Bluetooth spirometers, a free patient-facing Breathe Easy mobile app, and a web-based Provider Dashboard. It enables healthcare providers and decentralized clinical trials to capture pulmonary function data (FVC, FEV1, SVC, Peak Flow, FeNO, ePRO) remotely with real-time video coaching, AI spirometry overreading, automated alerts, and integrated reimbursement support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Remote spirometry with real-time video coaching provides reliable FEV1 measurement correlating closely with in-person spirometry suitable for clinical trials
+3 more records
Product overview1 text field

ZEPHYRx offers a modular decentralized respiratory monitoring platform comprising three core components: the Breathe Easy patient app (available on iOS, Android, Amazon), the cloud-based Provider Dashboard, and FDA-cleared MIR spirometers (Spirobank Smart for home use, Spirobank II Smart BLE for point-of-care Kiosk). The platform supports two primary testing modalities: Home for remote patient monitoring and Kiosk for point-of-care clinical trials. Gateway enables API-based integration into existing EMR systems and clinical trial platforms. The solution includes real-time video coaching, AI-powered spirometry overreading, gamified breathing exercises, custom surveys/ePROs, and automated alerts. ZEPHYRx also offers CRO Partner Program and RPM Partner Program for channel integration.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-15
Description

Strategic partnership with ActiGraph, a leading provider of wearable technology and scientific services for clinical drug development and academic research. Enables researchers to combine high-quality wearable behavior data with respiratory function data for comprehensive clinical trial insights.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-23
Description

Data integration partnership where ZEPHYRx respiratory monitoring data is now available to global scientists via the Target ALS Data Engine. Integrates ZEPHYRx data with rich clinical and biological datasets from Target ALS Global Natural History Study participants for freely accessible ALS research.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-05-17
Description

Strategic partnership integrating ZEPHYRx's respiratory platform with Morgan Scientific's ComPAS2 PFT software. Enables healthcare providers to monitor patient lung function at-home through an expanded remote spirometry offering powered by ZEPHYRx's respiratory cloud platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-02-08
Description

Partnership integrating FeNO by NIOX into the ZEPHYRx Respiratory Cloud Platform to offer one source of truth for multiple respiratory endpoints in clinical research. NIOX is the world leader in FeNO testing.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-09-19
Description

Partnership integrating ZEPHYRx cloud spirometry platform with RxCap's remote monitoring platform. Enables RxCap's enterprise customers (providers and payers) to monitor lung function of patients with pulmonary conditions through revenue-generating RPM programs integrated with existing care workflows.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-19
Description

Partnership in The Radcliff Study, a novel research-as-feasibility study by EverythingALS to develop an end-to-end digital alternative for the ALSFRS-R. ZEPHYRx joins Aural Analytics, FeetMe, and a major pharmaceutical company in this pre-competitive collaboration for ALS research.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-19
Description

Collaboration partner in EverythingALS Radcliff Study focused on developing digital alternatives for ALSFRS-R assessment in ALS research.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-19
Description

Collaboration partner in EverythingALS Radcliff Study focused on developing digital alternatives for ALSFRS-R assessment in ALS research.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-02-02
Description

Exclusive partnership for MIR to jointly market ZEPHYRx Remote Respiratory Monitoring (RRM) Solution in North America. ZEPHYRx is the largest reseller of MIR's Spirobank Smart Spirometer and has been working with MIR since its inception in 2019. MIR leverages its established customer base and sales personnel to accelerate ZEPHYRx's growth.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NuvoAir provides a digital respiratory care platform combining connected spirometers, mobile apps, and clinician dashboards for COPD and asthma management. It is a direct competitor in remote pulmonary function testing and virtual respiratory care, with overlapping provider and pharma customers.

TypeDirect peer
Description

Vivify Health is an RPM platform used by health systems and payers to manage chronic conditions remotely, including respiratory. It competes for the same hospital and payer RPM budgets as ZEPHYRx, and partners with similar device manufacturers for connected peripherals.

TypeEmerging player
Description

Strados Labs provides connected respiratory monitoring (wearable lung sound patches) used in clinical trials and provider care. It is an emerging player in connected respiratory data, and is already a ZEPHYRx partner in the multi-endpoint respiratory trial ecosystem.

TypeEmerging player
Description

Wellinks offers connected respiratory care for COPD and other chronic lung conditions, with an integrated spirometer, app, and coaching program. It is an emerging player with significant overlap in target patient population and provider use cases for remote pulmonary monitoring.

TypeDirect peer
Description

Propeller Health, now part of ResMed, is a direct respiratory RPM competitor offering connected inhalers and a digital platform for asthma and COPD. It targets the same healthcare-provider and pharma-sponsored patient populations as ZEPHYRx and is the most established comparable in the connected-respiratory space.

TypeDirect peer
Description

Medidata's decentralized trial platform and eCOA/ePRO solutions are used by the same CRO and pharma sponsors ZEPHYRx serves for respiratory clinical trials. It is a direct peer in the decentralized and hybrid respiratory trial endpoint market, though with a much broader modality footprint.

TypeOthers
Description

RxCap is a remote monitoring enablement platform for providers and payers, already integrated with ZEPHYRx for respiratory RPM. It is a partner/complementary platform rather than a direct competitor, competing only at the multi-condition RPM layer above the device-specific data.

TypeBroad incumbent
Description

Huma is a broader digital health and RPM platform used by hospitals, pharma, and CROs across multiple therapeutic areas including respiratory. It is a broad incumbent in the same buyer universe, with comparable regulatory and integration capabilities.

TypeDirect peer
Description

Castor is a clinical trial technology platform with eCOA, ePRO, and decentralized trial capabilities used by sponsors and CROs. It is a direct peer in the decentralized respiratory trial space, often evaluated alongside ZEPHYRx for data capture and remote monitoring.

10Biofourmis
TypeBroad incumbent
Description

Biofourmis is a broader RPM and hospital-at-home platform that increasingly covers respiratory and chronic care use cases. It is a broad incumbent in the same space, with overlapping buyers (health systems, payers, pharma) but a wider therapeutic footprint than ZEPHYRx's respiratory focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZEPHYRx

Remote Respiratory Monitoring (Digital Health SaaS)zephyrx.com

ZEPHYRx is a digital health SaaS platform combining FDA-cleared Bluetooth spirometers, a patient mobile app, and a cloud provider dashboard with AI spirometry overreading. It serves healthcare providers managing chronic respiratory patients and clinical research organizations running decentralized respiratory trials.

What ZEPHYRx does

ZEPHYRx is a digital health SaaS company providing cloud-based remote respiratory monitoring (RRM) for two primary customer segments: healthcare providers managing patients with chronic respiratory conditions (COPD, cystic fibrosis, pulmonary fibrosis, asthma, and related indications), and clinical research organizations, sponsors, and academic investigators running decentralized and hybrid respiratory clinical trials. Founded in 2019 and headquartered in Troy, New York, the company operates as ZEPHYRx LLC (Delaware-domiciled), is a subsidiary of My Music Machines Inc., and is majority-owned by Chairperson Sue Whalen with no institutional venture or growth-equity capital disclosed. The company originated from an NIH/NHLBI-funded STTR grant awarded to cofounder Michael DiCesare to develop a respiratory therapy device using interactive gaming and music, and gained initial traction during the COVID-19 pandemic by distributing connected spirometers for at-home pulmonary function testing to top US hospitals.

The ZEPHYRx platform is a three-layer architecture: a patient-facing Breathe Easy mobile app (iOS, Android, and Amazon), FDA-cleared Bluetooth-enabled MIR Spirobank spirometers (single-patient home and multi-patient point-of-care kiosk variants), and a cloud-based Provider Dashboard that delivers real-time video coaching, AI-driven spirometry overreading against ATS/ERS 2019 standards, custom surveys, compliance monitoring, and automated alerts. The platform captures spirometry endpoints (FVC, FEV1, SVC, Peak Flow), FeNO via NIOX integration, and ePRO/eCOA, and is HIPAA, GDPR, CCPA, and SOC 2 compliant. Trial-side modules include Kiosk for point-of-care testing, Home for at-home monitoring, and a Gateway API integration layer; healthcare-side modules include EMR integration and SSO connectors. Strategic integrations extend the platform to Morgan Scientific (ComPAS2), RxCap, ActiGraph wearables, and the Target ALS Data Engine.

ZEPHYRx monetizes through a per-patient-per-month subscription for healthcare providers (which only bills when a test is performed), hardware resale of MIR spirometers (ZEPHYRx is MIR's largest reseller), and clinical research services including trial setup, project management, global logistics, and data management. Distribution is hybrid: direct enterprise field sales, an exclusive North American channel partnership with MIR, CRO and RPM partner programs for white-label and indirect distribution, and self-serve patient app distribution through app stores. To date the company has delivered more than 40,000 spirometers, supported 50+ clinical studies covering CF, ALS, COPD, asthma, IPF, ILD, and other respiratory indications, and monitored 10,000+ research participants remotely.

ZEPHYRx firmographics

Firmographics
Name
ZEPHYRx
Legal name
ZEPHYRx LLC
Website
https://zephyrx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
ZEPHYRx is a digital health SaaS platform combining FDA-cleared Bluetooth spirometers, a patient mobile app, and a cloud provider dashboard with AI spirometry overreading. It serves healthcare providers managing chronic respiratory patients and clinical research organizations running decentralized respiratory trials.
Ownership category
akta.pro rank

ZEPHYRx industry classification

Industry
Product category
Remote Respiratory Monitoring (Digital Health SaaS)
NAICS
Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAI
Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Remote respiratory monitoring
  • Decentralized clinical trials
  • Spirometry cloud platform
  • Pulmonary function testing
  • Digital health SaaS

Where ZEPHYRx is headquartered

Location

Headquarters

HQ city
Troy
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ZEPHYRx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Subscription - Remote Respiratory Monitoring: Subscription-based model for cloud platform access and remote respiratory monitoring services. Subscribers pay a flat rate per patient per month with testing-inclusive pricing - if no test is performed, no charge; multiple tests still incur only the flat rate. Includes reimbursement support services, patient onboarding, and technical support.
  2. Spirometer Hardware Sales: Sales of MIR Spirobank Smart and Spirobank II Smart BLE FDA-cleared spirometers. ZEPHYRx is the largest reseller of MIR spirometers. Spirometers are sold to healthcare practices and clinical research organizations for at-home and point-of-care use.
  3. Clinical Research Services: Comprehensive services for decentralized and hybrid clinical trials including trial setup and kickoff, project management, data management, global logistics, 24/7 support, and compliance with GCP standards.
  4. RPM Reimbursement Support: Reimbursement services included in subscription to help providers navigate home spirometry reimbursement challenges with ongoing support and documentation for CPT code submissions.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlySubscription - Cost-Effective RRM Solution

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

ZEPHYRx product offering

Product offering

Core offering

ZEPHYRx provides a cloud-based Remote Respiratory Monitoring (RRM) platform that combines FDA-cleared Bluetooth spirometers, a free patient-facing Breathe Easy mobile app, and a web-based Provider Dashboard. It enables healthcare providers and decentralized clinical trials to capture pulmonary function data (FVC, FEV1, SVC, Peak Flow, FeNO, ePRO) remotely with real-time video coaching, AI spirometry overreading, automated alerts, and integrated reimbursement support.

Product overview

ZEPHYRx offers a modular decentralized respiratory monitoring platform comprising three core components: the Breathe Easy patient app (available on iOS, Android, Amazon), the cloud-based Provider Dashboard, and FDA-cleared MIR spirometers (Spirobank Smart for home use, Spirobank II Smart BLE for point-of-care Kiosk). The platform supports two primary testing modalities: Home for remote patient monitoring and Kiosk for point-of-care clinical trials. Gateway enables API-based integration into existing EMR systems and clinical trial platforms. The solution includes real-time video coaching, AI-powered spirometry overreading, gamified breathing exercises, custom surveys/ePROs, and automated alerts. ZEPHYRx also offers CRO Partner Program and RPM Partner Program for channel integration.

Differentiator

Problem solved

Functional benefit

Brands

  • Breathe Easy: Free patient-facing mobile application for performing pulmonary function tests, featuring real-time video coaching, PFT notifications, and gamified breathing exercises.

Quantifiable outcome

  • Remote spirometry with real-time video coaching provides reliable FEV1 measurement correlating closely with in-person spirometry suitable for clinical trials
  • +3 more outcomes

Companies that use ZEPHYRx

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

ZEPHYRx technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability4 records

Feature9 records

ZEPHYRx partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

  • ActiGraphcoreStrategic or Co-development Partner · 15 May 2025Strategic partnership with ActiGraph, a leading provider of wearable technology and scientific services for clinical drug development and academic research. Enables researchers to combine high-quality wearable behavior data with respiratory function data for comprehensive clinical trial insights.
  • Target ALScoreStrategic or Co-development Partner · 23 October 2024Data integration partnership where ZEPHYRx respiratory monitoring data is now available to global scientists via the Target ALS Data Engine. Integrates ZEPHYRx data with rich clinical and biological datasets from Target ALS Global Natural History Study participants for freely accessible ALS research.
  • Morgan ScientificcoreTechnology or Integration · 17 May 2024Strategic partnership integrating ZEPHYRx's respiratory platform with Morgan Scientific's ComPAS2 PFT software. Enables healthcare providers to monitor patient lung function at-home through an expanded remote spirometry offering powered by ZEPHYRx's respiratory cloud platform.
  • NIOXcoreTechnology or Integration · 8 February 2024Partnership integrating FeNO by NIOX into the ZEPHYRx Respiratory Cloud Platform to offer one source of truth for multiple respiratory endpoints in clinical research. NIOX is the world leader in FeNO testing.
  • RxCapcoreTechnology or Integration · 19 September 2022Partnership integrating ZEPHYRx cloud spirometry platform with RxCap's remote monitoring platform. Enables RxCap's enterprise customers (providers and payers) to monitor lung function of patients with pulmonary conditions through revenue-generating RPM programs integrated with existing care workflows.
  • EverythingALScoreStrategic or Co-development Partner · 19 September 2022Partnership in The Radcliff Study, a novel research-as-feasibility study by EverythingALS to develop an end-to-end digital alternative for the ALSFRS-R. ZEPHYRx joins Aural Analytics, FeetMe, and a major pharmaceutical company in this pre-competitive collaboration for ALS research.
  • Aural AnalyticsminorStrategic or Co-development Partner · 19 September 2022Collaboration partner in EverythingALS Radcliff Study focused on developing digital alternatives for ALSFRS-R assessment in ALS research.
  • FeetMeminorStrategic or Co-development Partner · 19 September 2022Collaboration partner in EverythingALS Radcliff Study focused on developing digital alternatives for ALSFRS-R assessment in ALS research.
  • MIR (Medical International Research)flagshipChannel Partner/ Reseller/ Distributor · 2 February 2022Exclusive partnership for MIR to jointly market ZEPHYRx Remote Respiratory Monitoring (RRM) Solution in North America. ZEPHYRx is the largest reseller of MIR's Spirobank Smart Spirometer and has been working with MIR since its inception in 2019. MIR leverages its established customer base and sales personnel to accelerate ZEPHYRx's growth.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

ZEPHYRx competitors and assessment

Company assessment

Direct peers

  • NuvoAir: NuvoAir provides a digital respiratory care platform combining connected spirometers, mobile apps, and clinician dashboards for COPD and asthma management. It is a direct competitor in remote pulmonary function testing and virtual respiratory care, with overlapping provider and pharma customers.
  • Vivify Health: Vivify Health is an RPM platform used by health systems and payers to manage chronic conditions remotely, including respiratory. It competes for the same hospital and payer RPM budgets as ZEPHYRx, and partners with similar device manufacturers for connected peripherals.
  • Propeller Health (ResMed): Propeller Health, now part of ResMed, is a direct respiratory RPM competitor offering connected inhalers and a digital platform for asthma and COPD. It targets the same healthcare-provider and pharma-sponsored patient populations as ZEPHYRx and is the most established comparable in the connected-respiratory space.
  • Medidata (Dassault Systèmes): Medidata's decentralized trial platform and eCOA/ePRO solutions are used by the same CRO and pharma sponsors ZEPHYRx serves for respiratory clinical trials. It is a direct peer in the decentralized and hybrid respiratory trial endpoint market, though with a much broader modality footprint.
  • Castor EDC: Castor is a clinical trial technology platform with eCOA, ePRO, and decentralized trial capabilities used by sponsors and CROs. It is a direct peer in the decentralized respiratory trial space, often evaluated alongside ZEPHYRx for data capture and remote monitoring.

Emerging players

  • Strados Labs: Strados Labs provides connected respiratory monitoring (wearable lung sound patches) used in clinical trials and provider care. It is an emerging player in connected respiratory data, and is already a ZEPHYRx partner in the multi-endpoint respiratory trial ecosystem.
  • Wellinks: Wellinks offers connected respiratory care for COPD and other chronic lung conditions, with an integrated spirometer, app, and coaching program. It is an emerging player with significant overlap in target patient population and provider use cases for remote pulmonary monitoring.

Others

  • RxCap: RxCap is a remote monitoring enablement platform for providers and payers, already integrated with ZEPHYRx for respiratory RPM. It is a partner/complementary platform rather than a direct competitor, competing only at the multi-condition RPM layer above the device-specific data.

Broad incumbents

  • Huma (formerly Huma Therapeutics): Huma is a broader digital health and RPM platform used by hospitals, pharma, and CROs across multiple therapeutic areas including respiratory. It is a broad incumbent in the same buyer universe, with comparable regulatory and integration capabilities.
  • Biofourmis: Biofourmis is a broader RPM and hospital-at-home platform that increasingly covers respiratory and chronic care use cases. It is a broad incumbent in the same space, with overlapping buyers (health systems, payers, pharma) but a wider therapeutic footprint than ZEPHYRx's respiratory focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ZEPHYRx social profiles

Digital presence

ZEPHYRx compliance and trust

Trust signal

Compliance5 records

ZEPHYRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZEPHYRx leadership team

Management profile

Number of profiles

Profiles11 records

ZEPHYRx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZEPHYRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZEPHYRx

What does ZEPHYRx do?

ZEPHYRx provides a cloud-based Remote Respiratory Monitoring (RRM) platform that combines FDA-cleared Bluetooth spirometers, a free patient-facing Breathe Easy mobile app, and a web-based Provider Dashboard. It enables healthcare providers and decentralized clinical trials to capture pulmonary function data (FVC, FEV1, SVC, Peak Flow, FeNO, ePRO) remotely with real-time video coaching, AI spirometry overreading, automated alerts, and integrated reimbursement support.

Is ZEPHYRx a public or private company?

ZEPHYRx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ZEPHYRx founded?

ZEPHYRx was founded in 2019. It employs 11 to 50 people.

Where is ZEPHYRx based?

ZEPHYRx is headquartered in Troy, United States, in the North America region.

How does ZEPHYRx make money?

Four revenue lines are on record. Subscription - Remote Respiratory Monitoring is the primary driver. The others are spirometer Hardware Sales, clinical Research Services and RPM Reimbursement Support.

Who are ZEPHYRx's main competitors?

Direct peers on record are NuvoAir, Vivify Health, Propeller Health (ResMed), Medidata (Dassault Systèmes) and Castor EDC. Emerging players are Strados Labs and Wellinks. RxCap is listed as an others. Broad incumbents are Huma (formerly Huma Therapeutics) and Biofourmis.

Does ZEPHYRx have an API?

Yes. ZEPHYRx offers an API for EMR integration, enabling healthcare providers to integrate patient PFT data into their Electronic Medical Records system. The API Guide is described as simple and designed for the provider's IT staff to easily integrate patient data. Additionally, Gateway enables clinical trials to integrate ZEPHYRx respiratory data into their preferred clinical trial management systems or existing remote patient monitoring platforms via API. Developer documentation is at Not specified.

What industry is ZEPHYRx in?

ZEPHYRx's product category is Remote Respiratory Monitoring (Digital Health SaaS). Its primary akta.pro industry code is HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea), with a secondary code of HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMorgan Scientific and ZEPHYRx have partnered to advance respiratory careMorgan Scientific and ZEPHYRx have announced a strategic partnership to advance respiratory care through integrated home spirometry monitoring solutions. The collaboration combines ZEPHYRx's respiratory cloud platform with Morgan Scientific's ComPAS2 PFT software, enabling real-time lung function data collection from patients at home with live video coaching features to ensure test quality. This integration aims to eliminate data disparity between point-of-care and remote lung function testing, providing healthcare providers with a comprehensive 360-degree view of patients' PFT history accessible through the top twenty EMRs.PR NewswireZEPHYRx and NIOX are working together to advance respiratory clinical researchZEPHYRx and NIOX have announced a partnership to integrate NIOX's FeNO testing technology into the ZEPHYRx Respiratory Cloud Platform for clinical research applications. The integration enables real-time capture and monitoring of FeNO measurements alongside other respiratory endpoints, allowing sponsors and researchers to view all endpoints in a single dashboard with historical trending and participant adherence monitoring. ZEPHYRx indicated plans for additional integrations in 2024 as it works toward becoming a single source of truth for respiratory research endpoints.PR NewswireZEPHYRx and MIR Join Forces to Market Remote Respiratory Monitoring Solutions to Healthcare Practices and Decentralized Clinical ResearchZEPHYRx, LLC and MIR (Medical International Research) announced an exclusive partnership to jointly market the ZEPHYRx Remote Respiratory Monitoring (RRM) Solution in North America, making it the only RPM solution offered by MIR in that region. ZEPHYRx, which has been the largest reseller of MIR's Spirobank Smart Spirometer since 2019, will leverage MIR's established customer base and sales personnel to accelerate growth. The companies cited increased demand for remote respiratory monitoring since COVID-19, particularly for patients with chronic conditions such as COPD, cystic fibrosis, pulmonary fibrosis, and asthma.